

Marios Politis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1691722/marios-politis-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers

6,445
citations

44
h-index

77
g-index

130
ext. papers

7,857
ext. citations

6.7
avg, IF

6.3
L-index

#	Paper	IF	Citations
124	Imaging Biomarkers in Huntington's Disease. <i>Neuromethods</i> , 2022 , 457-505	0.4	
123	Predictors of RBD progression and conversion to synucleinopathies.. <i>Current Neurology and Neuroscience Reports</i> , 2022 , 22, 93	6.6	1
122	Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer's disease spectrum. <i>Neurobiology of Aging</i> , 2021 , 97, 1-9	5.6	13
121	Serotonergic imaging in Parkinson's disease. <i>Progress in Brain Research</i> , 2021 , 261, 303-338	2.9	3
120	Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2021 , 179, 189-205	3	1
119	Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, 541-560	4.3	3
118	Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. <i>Cells</i> , 2020 , 9,	7.9	12
117	Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease. <i>Movement Disorders</i> , 2020 , 35, 1416-1427	7	22
116	Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. <i>Journal of Neurology</i> , 2020 , 267, 2042-2053	5.5	9
115	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020 , 19, 71-80	24.1	37
114	Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1). <i>Journal of Neural Transmission</i> , 2020 , 127, 51-59	4.3	2
113	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 1816-1830	5.3	10
112	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 163-169	3.6	5
111	[F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 366-378	8.8	6
110	Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo ¹¹ C-BU99008 PET study. <i>Brain</i> , 2019 , 142, 3116-3128	11.2	35
109	Cortical thinning across Parkinson's disease stages and clinical correlates. <i>Journal of the Neurological Sciences</i> , 2019 , 398, 31-38	3.2	28
108	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019 , 62, 201-209	3.6	9

107	Serotonergic pathology and disease burden in the premotor and motor phase of A53T β synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology, The</i> , 2019 , 18, 748-759	24.1	44
106	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1505-1515	7	10
105	Speech difficulties in early de novo patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 256-261	3.6	17
104	Neuroimaging in Lewy body dementia. <i>Journal of Neurology</i> , 2019 , 266, 1-26	5.5	27
103	Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment. <i>Journal of Neurology</i> , 2019 , 266, 1293-1302	5.5	63
102	Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson's patients. <i>PLoS ONE</i> , 2019 , 14, e0214352	3.7	7
101	Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. <i>Human Brain Mapping</i> , 2019 , 40, 5424-5442	5.9	57
100	Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. <i>BMC Neuroscience</i> , 2019 , 20, 55	3.2	6
99	Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2). <i>Journal of Neurology</i> , 2019 , 266, 1203-1210	5.5	9
98	Dementia spectrum disorders: lessons learnt from decades with PET research. <i>Journal of Neural Transmission</i> , 2019 , 126, 233-251	4.3	17
97	Hybrid PET-MRI Applications in Movement Disorders. <i>International Review of Neurobiology</i> , 2019 , 144, 211-257	4.4	8
96	Molecular Imaging of Dementia With Lewy Bodies. <i>International Review of Neurobiology</i> , 2019 , 144, 59-93	4.4	6
95	Cerebral serotonin transporter measurements with [C]DASB: A review on acquisition and preprocessing across 21 PET centres. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019 , 39, 210-222	7.3	21
94	Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018 , 18, 630-637	5.3	31
93	Diabetes mellitus and Parkinson disease. <i>Neurology</i> , 2018 , 90, e1654-e1662	6.5	84
92	Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 478-482	7	15
91	The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies. <i>Journal of Neural Transmission</i> , 2018 , 125, 1217-1223	4.3	19
90	Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. <i>Sleep Medicine</i> , 2018 , 43, 25-30	4.6	10

89	Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. <i>Brain</i> , 2018 , 141, 1501-1516	11.2	86
88	Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2018 , 387, 220-227	3.2	27
87	C-PE2I and F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. <i>Movement Disorders</i> , 2018 , 33, 117-127	7	30
86	Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 185-196	5.5	16
85	Imaging Markers of Progression in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 586-596	2.2	17
84	REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. <i>Neurology</i> , 2018 , 91, e894-e905	6.5	71
83	Imaging Transplantation in Movement Disorders. <i>International Review of Neurobiology</i> , 2018 , 143, 213-263	4.4	3
82	Neuroimaging of Sleep Disturbances in Movement Disorders. <i>Frontiers in Neurology</i> , 2018 , 9, 767	4.1	9
81	Structural Magnetic Resonance Imaging in Huntington's Disease. <i>International Review of Neurobiology</i> , 2018 , 142, 335-380	4.4	7
80	Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018 , 141, 131-172	4.4	15
79	Molecular Imaging in Huntington's Disease. <i>International Review of Neurobiology</i> , 2018 , 142, 289-333	4.4	4
78	PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. <i>Movement Disorders</i> , 2018 , 33, 1961-1965	7	18
77	Molecular Imaging of the Serotonergic System in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018 , 141, 173-210	4.4	18
76	Advances in MRI Methodology. <i>International Review of Neurobiology</i> , 2018 , 141, 31-76	4.4	51
75	Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 2413-2425	8.8	21
74	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 81-95	15	165
73	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. <i>Movement Disorders</i> , 2017 , 32, 181-192	7	56
72	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 217-231	15	458

71	Urinary dysfunction in early de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 939-940	7	7
70	Disease progression in LRRK2 parkinsonism. <i>Lancet Neurology</i> , 2017 , 16, 334-335	24.1	1
69	Imaging in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 132, 233-274	4.4	18
68	Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies. <i>Annals of Neurology</i> , 2017 , 81, 171-180	9.4	60
67	A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016) : Reply to Jean-Claude Baron Letter to Editor. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 548-550	8.8	
66	PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2017 , 17, 90	6.6	18
65	Imaging the Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 179-257	4.4	9
64	Chronic exposure to dopamine agonists affects the integrity of striatal D receptors in Parkinson's patients. <i>NeuroImage: Clinical</i> , 2017 , 16, 455-460	5.3	24
63	Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits. <i>Neurology</i> , 2017 , 89, 586-593	6.5	24
62	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. <i>Movement Disorders</i> , 2017 , 32, 235-240	7	14
61	Molecular Imaging Markers to Track Huntington's Disease Pathology. <i>Frontiers in Neurology</i> , 2017 , 8, 11	4.1	31
60	Be vigilant for dementia in Parkinson's disease. <i>Practitioner</i> , 2017 , 261, 11-5		18
59	A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 2244-2254	8.8	29
58	Imaging in Parkinson's disease. <i>Clinical Medicine</i> , 2016 , 16, 371-5	1.9	55
57	Serotonergic loss underlying apathy in Parkinson's disease. <i>Brain</i> , 2016 , 139, 2338-9	11.2	7
56	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. <i>Movement Disorders</i> , 2016 , 31, 1020-6	7	38
55	Cholinergic imaging in dementia spectrum disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1376-86	8.8	63
54	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107. <i>American Journal of Psychiatry</i> , 2016 , 173, 714-21	11.9	26

53	Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias. <i>Neurology</i> , 2016 , 86, 1152-8	6.5	60
52	Parkinson's Disease, Diabetes and Cognitive Impairment. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2016 , 10, 11-21		35
51	Current status of PET imaging in Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1171-82	8.8	58
50	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. <i>Journal of the Neurological Sciences</i> , 2016 , 368, 243-8	3.2	32
49	Molecular imaging of levodopa-induced dyskinesias. <i>Cellular and Molecular Life Sciences</i> , 2015 , 72, 2107-10.3		16
48	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. <i>Brain</i> , 2015 , 138, 3003-15	11.2	74
47	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. <i>Neurobiology of Aging</i> , 2015 , 36, 1736-1742	5.6	39
46	Single versus multiple impulse control disorders in Parkinson's disease: an ^{11}C -raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. <i>Journal of Neurology</i> , 2015 , 262, 1504-14	5.5	35
45	PET in multiple sclerosis. <i>Clinical Nuclear Medicine</i> , 2015 , 40, e46-52	1.7	13
44	Recent imaging advances in neurology. <i>Journal of Neurology</i> , 2015 , 262, 2182-94	5.5	25
43	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. <i>Neurobiology of Disease</i> , 2015 , 83, 115-21	7.5	87
42	Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1336-41	3.6	8
41	Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. <i>Brain</i> , 2015 , 138, 110-9	11.2	60
40	The X-Linked Hypothesis of Brain Disorders: Can Gender Ratios Tell Us Anything About Cellular Etiology of Neurodegenerative and Psychiatric Diseases?. <i>Neuroscientist</i> , 2015 , 21, 589-98	7.6	1
39	Serotonin in Parkinson's disease. <i>Behavioural Brain Research</i> , 2015 , 277, 136-45	3.4	167
38	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. <i>Brain</i> , 2015 , 138, 3016-29	11.2	71
37	Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. <i>Journal of Neurology</i> , 2015 , 262, 2653-61	5.5	30
36	Dopamine receptor mapping with PET imaging in Parkinson's disease. <i>Journal of Neurology</i> , 2014 , 261, 2251-63	5.5	39

35	Neuroimaging in Parkinson disease: from research setting to clinical practice. <i>Nature Reviews Neurology</i> , 2014 , 10, 708-22	15	158
34	Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. <i>Neurobiology of Disease</i> , 2014 , 65, 203-10	7.5	54
33	Problematic Internet use in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 482-7	3.6	12
32	Neuroimaging in Huntington's disease. <i>World Journal of Radiology</i> , 2014 , 6, 301-12	2.9	46
31	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1340-9	15.9	172
30	Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. <i>Aids</i> , 2014 , 28, 67-72	3.5	95
29	Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. <i>JAMA Neurology</i> , 2014 , 71, 83-7	17.2	205
28	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. <i>Brain</i> , 2013 , 136, 400-11	11.2	151
27	Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. <i>Neurology</i> , 2013 , 80, 1850-5	6.5	76
26	Ambient particulate matter and its potential neurological consequences. <i>Reviews in the Neurosciences</i> , 2013 , 24, 323-35	4.7	25
25	Clinical utility of DaTscan [®] (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2013 , 3, 33-39	5.4	4
24	Positron emission tomography imaging in neurological disorders. <i>Journal of Neurology</i> , 2012 , 259, 1769-80	9.5	58
23	In vivo imaging of the integration and function of nigral grafts in clinical trials. <i>Progress in Brain Research</i> , 2012 , 200, 199-220	2.9	14
22	Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. <i>PLoS ONE</i> , 2012 , 7, e38980	3.7	27
21	Clinical application of stem cell therapy in Parkinson's disease. <i>BMC Medicine</i> , 2012 , 10, 1	11.4	200
20	Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. <i>Science Translational Medicine</i> , 2012 , 4, 128ra41	17.5	92
19	Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. <i>Neurology</i> , 2012 , 79, 523-30	6.5	125
18	The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. <i>Brain</i> , 2012 , 135, 2449-57	11.2	52

17	Reduplicative paramnesia: a review. <i>Psychopathology</i> , 2012 , 45, 337-43	3.4	15
16	Impulse Control Disorders in Parkinson's Disease: A Review. <i>Current Psychiatry Reviews</i> , 2012 , 8, 235-246	0.9	1
15	Imaging of microglia in patients with neurodegenerative disorders. <i>Frontiers in Pharmacology</i> , 2012 , 3, 96	5.6	85
14	Serotonergic dysfunction in Parkinson's disease and its relevance to disability. <i>Scientific World Journal, The</i> , 2011 , 11, 1726-34	2.2	62
13	Serotonergic mediated body mass index changes in Parkinson's disease. <i>Neurobiology of Disease</i> , 2011 , 43, 609-15	7.5	36
12	Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease. <i>BMC Medicine</i> , 2011 , 9, 50	11.4	10
11	Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. <i>Movement Disorders</i> , 2011 , 26, 1997-2003	7	126
10	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. <i>Human Brain Mapping</i> , 2011 , 32, 258-70	5.9	147
9	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. <i>Brain</i> , 2011 , 134, 969-78	11.2	245
8	Positron emission tomography neuroimaging in Parkinson's disease. <i>American Journal of Translational Research (discontinued)</i> , 2011 , 3, 323-41	3	44
7	Brain imaging after neural transplantation. <i>Progress in Brain Research</i> , 2010 , 184, 193-203	2.9	13
6	Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. <i>Science Translational Medicine</i> , 2010 , 2, 38ra46	17.5	231
5	Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. <i>Neurobiology of Disease</i> , 2010 , 37, 356-61	7.5	49
4	Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. <i>Neurobiology of Disease</i> , 2010 , 40, 216-21	7.5	179
3	Parkinson's disease symptoms: the patient's perspective. <i>Movement Disorders</i> , 2010 , 25, 1646-51	7	359
2	Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. <i>Experimental Neurology</i> , 2008 , 214, 112-6	5.7	84
1	Hypothalamic involvement in Huntington's disease: an in vivo PET study. <i>Brain</i> , 2008 , 131, 2860-9	11.2	137